857 related articles for article (PubMed ID: 25565980)
1. Parkinson's disease: animal models and dopaminergic cell vulnerability.
Blesa J; Przedborski S
Front Neuroanat; 2014; 8():155. PubMed ID: 25565980
[TBL] [Abstract][Full Text] [Related]
2. RGS Proteins as Critical Regulators of Motor Function and Their Implications in Parkinson's Disease.
Ahlers-Dannen KE; Spicer MM; Fisher RA
Mol Pharmacol; 2020 Dec; 98(6):730-738. PubMed ID: 32015009
[TBL] [Abstract][Full Text] [Related]
3. Trib3 Is Elevated in Parkinson's Disease and Mediates Death in Parkinson's Disease Models.
Aimé P; Sun X; Zareen N; Rao A; Berman Z; Volpicelli-Daley L; Bernd P; Crary JF; Levy OA; Greene LA
J Neurosci; 2015 Jul; 35(30):10731-49. PubMed ID: 26224857
[TBL] [Abstract][Full Text] [Related]
4. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
Giguère N; Delignat-Lavaud B; Herborg F; Voisin A; Li Y; Jacquemet V; Anand-Srivastava M; Gether U; Giros B; Trudeau LÉ
PLoS Genet; 2019 Aug; 15(8):e1008352. PubMed ID: 31449520
[TBL] [Abstract][Full Text] [Related]
5. Neonatal 6-OHDA lesion of the SNc induces striatal compensatory sprouting from surviving SNc dopaminergic neurons without VTA contribution.
Tanguay W; Ducrot C; Giguère N; Bourque MJ; Trudeau LE
Eur J Neurosci; 2021 Oct; 54(7):6618-6632. PubMed ID: 34470083
[TBL] [Abstract][Full Text] [Related]
6. Loss of fragile X mental retardation protein precedes Lewy pathology in Parkinson's disease.
Tan Y; Sgobio C; Arzberger T; Machleid F; Tang Q; Findeis E; Tost J; Chakroun T; Gao P; Höllerhage M; Bötzel K; Herms J; Höglinger G; Koeglsperger T
Acta Neuropathol; 2020 Feb; 139(2):319-345. PubMed ID: 31768670
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease.
Liang CL; Wang TT; Luby-Phelps K; German DC
Exp Neurol; 2007 Feb; 203(2):370-80. PubMed ID: 17010972
[TBL] [Abstract][Full Text] [Related]
8. Viral overexpression of human alpha-synuclein in mouse substantia nigra dopamine neurons results in hyperdopaminergia but no neurodegeneration.
Moreno SIG; Limani F; Ludwig I; Gilbert C; Pifl C; Hnasko TS; Steinkellner T
bioRxiv; 2024 May; ():. PubMed ID: 38746104
[TBL] [Abstract][Full Text] [Related]
9. Surprising behavioral and neurochemical enhancements in mice with combined mutations linked to Parkinson's disease.
Hennis MR; Marvin MA; Taylor CM; Goldberg MS
Neurobiol Dis; 2014 Feb; 62():113-23. PubMed ID: 24075852
[TBL] [Abstract][Full Text] [Related]
10. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
11. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP.
Schober A
Cell Tissue Res; 2004 Oct; 318(1):215-24. PubMed ID: 15503155
[TBL] [Abstract][Full Text] [Related]
12. Synuclein Proteins in MPTP-Induced Death of Substantia Nigra Pars Compacta Dopaminergic Neurons.
Goloborshcheva VV; Kucheryanu VG; Voronina NA; Teterina EV; Ustyugov AA; Morozov SG
Biomedicines; 2022 Sep; 10(9):. PubMed ID: 36140378
[TBL] [Abstract][Full Text] [Related]
13. Differential contribution of Ih to the integration of excitatory synaptic inputs in substantia nigra pars compacta and ventral tegmental area dopaminergic neurons.
Masi A; Narducci R; Resta F; Carbone C; Kobayashi K; Mannaioni G
Eur J Neurosci; 2015 Nov; 42(9):2699-706. PubMed ID: 26354486
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effect of rotenone and 1‑methyl‑4‑phenyl‑1,2,3,6‑tetrahydropyridine on inducing chronic Parkinson's disease in mouse models.
Zhang J; Sun B; Yang J; Chen Z; Li Z; Zhang N; Li H; Shen L
Mol Med Rep; 2022 Mar; 25(3):. PubMed ID: 35039876
[TBL] [Abstract][Full Text] [Related]
15. Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.
Song LK; Ma KL; Yuan YH; Mu Z; Song XY; Niu F; Han N; Chen NH
PLoS One; 2015; 10(6):e0131281. PubMed ID: 26114655
[TBL] [Abstract][Full Text] [Related]
16. Nigral injection of a proteasomal inhibitor, lactacystin, induces widespread glial cell activation and shows various phenotypes of Parkinson's disease in young and adult mouse.
Savolainen MH; Albert K; Airavaara M; Myöhänen TT
Exp Brain Res; 2017 Jul; 235(7):2189-2202. PubMed ID: 28439627
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-124 in MPTP-treated mouse model of Parkinson's disease and MPP iodide-treated MN9D cells modulates the expression of the calpain/cdk5 pathway proteins.
Kanagaraj N; Beiping H; Dheen ST; Tay SS
Neuroscience; 2014 Jul; 272():167-79. PubMed ID: 24792712
[TBL] [Abstract][Full Text] [Related]
18. Targeting microglial NLRP3 in the SNc region as a promising disease-modifying therapy for Parkinson's disease.
Qiao C; Dang T; Zhou Y; Zhou YZ; Zhao R; Wang M
Brain Behav; 2022 Nov; 12(11):e2784. PubMed ID: 36199191
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein dynamics in induced pluripotent stem cell-derived dopaminergic neurons from a Parkinson's disease patient (PARK4) with SNCA triplication.
Fukusumi H; Togo K; Sumida M; Nakamori M; Obika S; Baba K; Shofuda T; Ito D; Okano H; Mochizuki H; Kanemura Y
FEBS Open Bio; 2021 Feb; 11(2):354-366. PubMed ID: 33301617
[TBL] [Abstract][Full Text] [Related]
20. Non-invasive systemic viral delivery of human alpha-synuclein mimics selective and progressive neuropathology of Parkinson's disease in rodent brains.
Bérard M; Martínez-Drudis L; Sheta R; El-Agnaf OMA; Oueslati A
Mol Neurodegener; 2023 Nov; 18(1):91. PubMed ID: 38012703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
